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S50 Lupus Nephropathyand renal relapse in 5 patients. C12 MPA level at the time of these events
were 1.7  1.6 mg/L, 2.6  1.7 mg/L and 1.5  0.9 mg/L respectively.
Conclusion: C12 MPA level demonstrated good correlation with drug expo-
sure, and may be associated with renal relapse and haematological side-ef-
fects but not infection.http://dx.doi.org/10.1016/j.hkjn.2015.08.133
0131
Clinicopathological Characteristics and Risk Factors of Lupus
Nephropathy with Hypertension
R. R. Rong, C. V. Chen, Z. Q. Zhou, W. Q. Wen, Y. X. Q. Yu
Department of Nephropathy, The First Affiliated Hospital of Sun Yat-sen
University, Guangzhou, China
Objectives: This study was embarked upon to investigate the clinical and
pathological features of LN patients with HTN and identify the risk factors
for mortality and development of ESRD in hypertensive LN patients.0131
Table 1. Clinical characteristics of 1406 LN patients.
Total (nZ1406) W
Age (year) 31.4512.58 3
Male (n, %) 241 (17.1%) 1
SLE course (month) 61 (11, 126) 6
LN course (month) 53 (9, 119) 5
SBP (mmHg) 129.1525.61 1
DBP (mmHg) 81.8316.78 8
AI score 6 (5,8) 7
CI score 3 (2,4) 4
AKI (n ,%) 222 (15.8%) 1
CKD staging
Stage 1 715 (38.6%) 1
Stage 2 198 (19.9%) 1
Stage 3 222 (17.6%) 1
Stage 4 126 (10.7%) 1
Stage 5 134 (13.1%) 1
Scr (mmol/L) 175.52104.34 2
Scr>133 mmol/L 484 (34.4%) 3
BUN（mmol/L） 12.129.66 1
eGFR (mL/min/1.73m2) 79.3664.72 5
Hb(g/l) 94.3027.03 8
24h urine protein excretion(g/24h) 2.530.73 2
ANA (positive) 1301 (92.5%) 6
dsDNA (positive) 1063 (75.6%) 5
Sm (positive) 413 (29.4%) 2
C3 (mmo/L) 0.510.27 0
Cholesterol (mmol/L) 6.082.54 6
TG (mmol/L) 2.461.54 2
HDL-c (mmol/L) 1.100.50 1
LDL-c (mmol/L) 3.511.74 3
ALB (g/L) 27.627.37 2
UA (mmol/L) 438.54251.46 4
Ca (mmol/L) 2.000.29 1
P (mmol/L) 1.470.54 1
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Table 2. Pathological characteristics of the LN cohort.
Total (nZ1406)
Global glomerular sclerosis (n, %) 405 (28.8%）
Crescent (n, %) 474 (33.7%）
Platinum ear-pick (n, %) 296 (21.1%）
Endocapillary hypercellularity (n, %)
<25% 300 (21.3%）
25%-50% 385 (27.4%）
50% 249 (17.7%）
Karyorrhexis (n, %)
Without (0%) 540 (38.4%)
Mild (0-25%) 324 (23.0%)
Moderate (25%-50%) 61 (4.3%)
Severe (50%) 16 (1.1%)Methods: This was a retrospective cohort study. A total of 1406 LN patients
were included. Cox regression was used to analyze the relationship between
clinicopathological indices and hypertension.
Results: Of the 1406 LN patients enrolled in this study, 764 of them
manifested with hypertension. Compared to LN patients without hyper-
tension, hypertensive LN patients were presented with older age, higher
active index (AI) an chronic index (CI) score, more proportion of
advanced chronic kidney disease (CKD) staging, higher level of serum
creatinine, blood urea nitrogen (BUN), cholesterol, trigryceride (TG),
low density lipoprotein-cholesterol (LDL-c), uric acid (UA), serum phos-
phorus (P) and 24-hour urine protein excretion. With respect to patho-
logical characteristics, more proportion of global glomerular sclerosis,
crescents, platinum ear-pick, endocapillary hypercellularity and intersti-
tial abnormality were observed in hypertensive LN patients (Table 1).
Hypertension per se was a risk factor of ESRD and serum doubling in
LN patients 2 adjusted for age, gender, albumin, cholesterol, SLEDAI,
immune suppressant, corticoid steroid, and pathological classification
(Table 2, Figures 1e3).
Conclusion: Hypertension per se was a risk factor of renal function deterio-
ration. The effect of hypertension to mortality is not significant.ith HTN (nZ764) Without HTN (nZ642) p
3.2313.29 29.3411.34 <0.001
44 (18.8%) 97 (15.1%) 0.064
0 (9.2, 128) 61 (12, 124) 0.797
3.5 (8, 119) 52 (9.7, 119) 0.643
42.2524.96 113.5715.78 <0.001
9.8016.70 72.3610.93 <0.001
(5,9) 6 (4,8) <0.001
(2,5) 3 (2,4) <0.001
54 (20.2%) 68 (10.6%) <0.001
<0.001
81 (23.7%) 363 (56.6%)
55 (20.3%) 125 (19.5%)
49 (19.5%) 99 (15.4%)
15 (15.1%) 35 (5.5%)
64 (21.5%) 20 (3.1%)
33.50103.45 106.5158.04 <0.001
8 3(50.1%) 111 (17.3%) <0.001
5.0110.50 8.707.20 <0.001
8.8447.42 103.7973.53 <0.001
9.5926.00 100.0027.18 <0.001
.901.2 2.010.45 <0.001
99 (91.5%) 602 (93.8%) 0.108
73 (75%) 490 (76.3%) 0.576
17 (28.4%) 196 (30.5%) 0.383
.520.26 0.510.28 0.684
.372.67 5.732.33 <0.001
.621.66 2.271.37 <0.001
.100.50 1.120.51 0.460
.671.80 3.321.65 <0.001
6.906.97 28.497.74 <0.001
68.11203.96 402.67295.38 <0.001
.990.29 2.010.28 <0.001
.580.62 1.350.40 <0.001
With HTN (nZ764) Without HTN (nZ642) p
251 (32.9%) 154 (24.0%) <0.001
289 (37.8%) 185 (28.8%) <0.001
174 (22.8%) 122 (19.0%) 0.002
<0.001
131 (17.1%) 169 (26.3%)
192 (25.1%) 193 (30.1%)
155 (20.3%) 94 (14.6%)
0.478
271 (35.5%) 269 (41.9%)
168 (22.0%) 156 (24.3%)
36 (4.7%) 25 (3.9%)
6 (0.8%) 10 (1.6%)
Loop necrosis (n, %) 0.902
Without (0%) 852 (60.6%) 436 (57.1%) 416 (64.8%)
Mild (0-25%) 78 (5.5%) 40 (5.2%) 38 (5.9%)
Moderate (25%-50%) 8 (0.6%) 4 (0.5%) 4 (0.6%)
Severe (50%) 3 (0.2%) 1 (0.1%) 2 (0.3%)
Tubular necrosis (n, %) 55 (3.9%) 29 (3.8%) 26 (4.0%) 0.986
Tubular atrophy (n, %) <0.001
<25% 403 (28.7%) 363 (47.6%) 417 (64.9%)
25%-50% 109 (7.8%) 75 (9.8%) 34 (5.3%)
50%-75% 32 (2.3%) 25 (3.3%) 7 (1.1%)
75% 20 (1.4%) 18 (2.4%) 2 (0.3%)
Interstitial infiltrates (n, %) <0.001
<25% 745 (53%) 347 (45.5%) 398 (62%)
25%-50% 127 (9.0%) 82 (10.7%) 45 (7.0%)
50%-75% 37 (2.6%) 24 (3.1%) 13 (2.0%)
75% 31 (2.2%) 27 (3.5%) 4 (0.6%)
Interstitial fibrosis (n, %) <0.001
<25% 802 (57%) 377 (49.4%) 425 (66.3%)
25%-50% 91 (6.5%) 64 (8.4%) 27 (4.2%)
50%-75% 27 (1.9%) 22 (2.9%) 5 (0.8%)
75% 19 (1.4%) 16 (2.1%) 3 (0.5%)
Endocapillary thrombosis (n, %) 174 (12.4%) 108 (14.1%) 66 (10.3%) 0.001
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Table 3. Cox regression models assessing hypertension as a risk factor of mortality, ESRD, creatinine doubling
Unadjusted Model 1 Model 2
HR (95%CI) p HR (95%CI) p HR (95%CI) p
Mortality
SBP 1.19 (1.10,1.29) <0.001 1.15 (1.06,1.25) 0.001 1.15 (1.05,1.26) 0.003
DBP 1.21 (1.07,1.38) 0.003 1.21 (1.06,1.38) 0.005 1.19 (1.03,1.38) 0.017
MAP 1.24 (1.11,1.39) <0.001 1.21 (1.08,1.36) 0.001 1.20 (1.06,1.37) 0.005
Hypertension 1.74 (1.22, 2.48) 0.002 1.55 (1.08, 2.22) 0.018 1.56 (0.90, 2.70) 0.113
ESRD
SBP 1.20 (1.01,1.32) <0.001 1.20 (1.08,1.32) <0.001 1.16 (1.05,1.30) 0.005
DBP 1.17 (1.00,1.37) 0.058 1.16 (0.99,1.36) 0.073 1.08 (0.91,1.28) 0.40
MAP 1.22 (1.07,1.41) 0.004 1.21 (1.05,1.40) 0.007 1.15 (0.99,1.34) 0.075
Hypertension 2.45 (1.61, 3.74) <0.001 2.36 (1.54, 3.61) <0.001 2.54 (1.30, 4.97) 0.006
Serum creatinine doubling
SBP 1.16 (1.07,1.26) <0.001 1.16 (1.06,1.27) 0.001 1.13 (1.03,1.24) 0.010
DBP 1.08 (0.94,1.24) 0.272 1.07 (0.93,1.23) 0.328 1.01 (0.87,1.17) 0.926
MAP 1.15 (1.02,1.30) 0.022 1.14 (1.01,1.29) 0.037 1.09 (0.95,1.24) 0.22
Hypertension 2.34 (1.63, 3.35) <0.001 2.26 (1.56, 3.26) <0.001 2.30 (1.40, 3.78) 0.002
Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, albumin, cholesterol, SLEDAI, immune suppressant, corticoid steroid, and pathological classification
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S52 Lupus NephropathyFigures 1e3. Continuous blood pressure (SBP & DBP & MAP) and logHR curve
(Scr doubling, ESRD,mortality): 3 figures, eachwith 3 plots for SBP, DBP&MAP.http://dx.doi.org/10.1016/j.hkjn.2015.08.134
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Objectives: To investigate the prevalence of dyslipidemia in Chinese lupus
nephropathy (LN) patients and examine differences in clinical characteris-
tics and outcomes between LN patients with and without dyslipidemia.
Methods: We included 1,150 LN patients registered from January 1, 2006 to
December 31, 2011 in our databank. Patients were divided into baseline dys-
lipidemia and non-dyslipidemia groups according to NCEP ATPIII criterion.
Logistic and Cox regression analyses modelswere used to explorerelated
risk factors (clinical, laboratory and treatment factors) for dyslipidemia
and their effects on all-cause mortality, CVD mortality, doubling creatinine
and end-stage renal disease (ESRD), respectively.
Results: The prevalence rate of dyslipidemia in LN patients was 91.4% in our
center. Patients with dyslipidemia showed severe proteinuria, higher SLE-
DAI, higher rate of hypertension, AKI, hyperuricemia, hypoalbuminemia,
crescents and interstitial inflammation than patients with normal lipids.
Multivariate logistic regression analysis indicated that high triglyceride and
low HDL-C were associated with SLEDAI (OR Z 1.05, 95% CI: 1.02e1.08,
P< 0.001 and OR Z 1.04, 95% CI: 1.01e1.07, P Z 0.001, respectively) and
eGFR (OR Z 0.97, 95% CI: 0.94e0.99, P Z 0.044 and OR Z 0.96, 95% CI:
0.93e0.99, P Z 0.003, respectively). 24-hour proteinuria was associated
with high total cholesterol (ORZ 1.24, 95% CI: 1.16e1.33), high triglyceride
(OR Z 1.14, 95% CI: 1.07e1.22) and high LDL-C (OR Z 1.15, 95% CI:
1.09e1.21) (all P values< 0.001). During a median follow-up of 56 months
(1e206months), 815 patients (71%) completed the follow-up, of which 100
patients (12%) experienced doubling creatinine, 76 (9%) had ESRD, and
102(13%) deaths occurred, 20(20%) of which were associated with CVD. In
Cox analysis, low HDL-C was associated with all-cause mortality (HR 2.47,
95% CI 1.05e5.79, P Z 0.038) after adjustment for age, gender, eGFR, hy-
pertension, hypoalbuminemia, SLEDAI, lipid-modifying and immunosuppres-
sive treatment.
Conclusion: Our results indicate that dyslipidemia was common in Chinese
LN patients. Low baseline HDL-C level increases risk of all-cause mortality,
which indicates that HDL-C might play an important role in prognosis of
LN.http://dx.doi.org/10.1016/j.hkjn.2015.08.1350135
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Objective: We aimed to assess the long-term prognosis in LN patients with
different proportions of crescents.
Methods: In this single-center, retrospective cohort study, 788 eligible LN
patients were enrolled from January, 1996 to December, 2011. Primary
endpoint was defined as a composite of doubling of baseline serum creati-
nine and ESRD, and the secondary endpoint was death.
Results:Among788 LNpatients, therewere406 patients presenting crescents at
biopsy. Comparisons between patients with and without crescent revealed that
crescent-featured individuals had worse baseline conditions in light of lower
eGFR (p< 0.001), higher blood pressure (p< 0.001), heavier proteinuria
(p< 0.001), severer microscope hematuria (p< 0.001), higher pathological
scores of activity index (AI) (p< 0.001) and chronicity index (CI) (p< 0.001).
Overamedian follow-up timeof56months (range:1e172months),nosignificant
differences were observed in both 10-year renal survival (86.2 vs. 89.7%,
p Z 0.637) and patient survival (84.3% vs. 89.2%, p Z 0.188). Crescent failed
to be the determinant of the composite endpoint comprising creatinine
doubling, ESRD and death (HRZ 0.82, 95% CI: 0.39e1.73, pZ 0.610). Besides,
weobserved that the increase in crescent proportion negatively related to base-
line eGFR (p-trend< 0.001), serum levels of hemoglobin (p-trend< 0.001), uric
acid(p-trendZ0.002), andpositivelyparalleledwithdegreesofpathologicalac-
tivity (AI:p-trend< 0.01) andchronicity (CI: p-trendZ0.003).CrescenticLNpa-
tientsexhibitedtheworst survivalwithanestimated5-year survival rateof78.9%
and 10-year of 52.6% (pZ 0.008). Higher proportion of crescents was demon-
strated to be an independent predictor of adverse outcomes (increase by every
10%: HR 1.17, 95% CI: 1.01e1.35, p Z 0.034) adjusting for age, sex, baseline
eGFR, proteinuria, AI and CI in multivariate Cox proportional hazard model.
Conclusion: The present cohort study showed that the overall long-term
renal survival of LN patients with and without crescents appeared compara-
ble, while increasing crescent proportion carried mounting risk of renal pro-
gression and death.Figure 1. Patient survival of LN with different proportions of crescents.http://dx.doi.org/10.1016/j.hkjn.2015.08.136
